Hepatitis C Treatment Wins Approval, but Price Relief May Be Limited
Saturday, December 20, 2014 - 01:20
in Mathematics & Economics
Insurers are hoping that a new competitor to Gilead Sciences’ drugs for the disease will drive down prices, though the new drug’s price is higher than was hoped.